All In Biotech

Drug Trial Radar · NCT05487404

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

A Double-Blind Clinical Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Nov 15, 2021

Primary completion

May 29, 2022

Study completion May 29, 2022

Sponsor

Lead sponsor
Aldeyra Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Double-Blind Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels

Conditions

  • Ethanol Intoxication

Interventions

  • ADX-629Drug

    3 oral doses of ADX-629 600 milligrams

  • PlaceboDrug

    3 oral doses of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Serious Adverse EventsTime frame: The safety assessment period was approximately two days for each treatment period.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medpace Clinical Pharmacology

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.